Circulating resistin is a significant predictor of mortality independently from cardiovascular comorbidities in elderly, non-diabetic subjects with chronic kidney disease

References

• Axelsson J, Witasp A, Carrero JJ, et al. (2007). Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. Am J Kidney Dis 49:237–44
   PubMed Web of Science ®Google Scholar
• Banerjee RR, Rangwala SM, Shapiro JS, et al. (2004). Regulation of fasted blood glucose by resistin. Science 303:1195–8
   PubMed Web of Science ®Google Scholar
• Chen SC, Hung CC, Tsai YC, et al. (2013). Association of cholesterol levels with mortality and cardiovascular events among patients with CKD and different amounts of proteinuria. Clin J Am Soc Nephrol 8:1915–26
   PubMed Web of Science ®Google Scholar
• Cheung AK, Sarnak MJ, Yan G, et al. (2004). Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney Int 65:2380–9
   PubMed Web of Science ®Google Scholar
• Cockcroft DW, Gault MH. (1976). Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41
   PubMed Web of Science ®Google Scholar
• Dalamaga M. (2013). Interplay of adipokines and myokines in cancer pathophysiology: emerging therapeutic implications. World J Exp Med 3:26–33
   PubMedGoogle Scholar
• Dalamaga M. (2014). Resistin as a biomarker linking obesity and inflammation to cancer: potential clinical perspectives. Biomark Med 8:1–12
   PubMed Web of Science ®Google Scholar
• Dalamaga M, Karmaniolas K, Nikolaidou A, et al. (2008). Adiponectin and resistin are associated with risk for myelodysplastic syndrome, independently from the IGF-I system. Eur J Cancer 44:1744–53
   PubMed Web of Science ®Google Scholar
• Dalamaga M, Karmaniolas K, Panagiotou A, et al. (2009). Low circulating adiponectin and resistin, but not leptin, levels are associated with multiple myeloma risk: a case-control study. Cancer Causes Control 20:193–9
   PubMed Web of Science ®Google Scholar
• Dalamaga M, Karmaniolas K, Papadavid E, et al. (2013a). Hyperresistinemia is associated with postmenopausal breast cancer. Menopause 20:845–51
   PubMed Web of Science ®Google Scholar
• Dalamaga M, Sotiropoulos G, Karmaniolas K, et al. (2013b). Serum resistin: a biomarker of breast cancer in postmenopausal women? Association with clinicopathological characteristics, tumor markers, inflammatory and metabolic parameters. Clin Biochem 46:584–90
   PubMed Web of Science ®Google Scholar
• Dandona P, Ghanim H, Bandyopadhyay A, et al. (2010). Insulin suppresses endotoxin-induced oxidative, nitrosative, and inflammatory stress in humans. Diabetes Care 33:2416–23
   PubMed Web of Science ®Google Scholar
• Erer HB, Sayar N, Guvenc TS, et al. (2014). Prognostic value of serum resistin levels in patients with acute myocardial infarction. Kardiol Pol 72:181–6
   PubMed Web of Science ®Google Scholar
• Forsblom C, Thomas MC, Moran J, et al. (2011). Serum adiponectin concentration is a positive predictor of all-cause and cardiovascular mortality in type 1 diabetes. J Intern Med 270:346–55
   PubMed Web of Science ®Google Scholar
• Kanbay M, Yilmaz MI, Sonmez A, et al. (2012). Serum uric acid independently predicts cardiovascular events in advanced nephropathy. Am J Nephrol 36:324–31
   PubMed Web of Science ®Google Scholar
• Karmiris K, Koutroubakis IE, Xidakis C, et al. (2006). Circulating levels of leptin, adiponectin, resistin and ghrelin in inflammatory bowel disease. Inflamm Bowel Dis 12:100–5
   PubMed Web of Science ®Google Scholar
• Kaser S, Kaser A, Sandhofer A, et al. (2003). Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun 309:286–90
   PubMed Web of Science ®Google Scholar
• Koch A, Gressner OA, Sanson E, et al. (2009). Serum resistin levels in critically ill patients are associated with inflammation, organ dysfunction and metabolism and may predict survival of non-septic patients. Crit Care 13:R95
   PubMed Web of Science ®Google Scholar
• Kovesdy CP, George SM, Anderson JE, et al. (2009). Outcome predictability of biomarkers of protein-energy wasting and inflammation in moderate and advanced chronic kidney disease. Am J Clin Nutr 90:407–14
   PubMed Web of Science ®Google Scholar
• Lee SE, Kim HS. (2012). Human resistin in cardiovascular disease. J Smooth Muscle Res 48:27–35
   PubMedGoogle Scholar
• Liabeuf S, Barreto DV, Kretschmer A, et al. (2011). High circulating levels of large splice variants of tenascin-C is associated with mortality and cardiovascular disease in chronic kidney disease patients. Atherosclerosis 215:116–24
   PubMed Web of Science ®Google Scholar
• Marouga A, Dalamaga M, Kastania AN, et al. (2013). Correlates of serum resistin in elderly, non-diabetic patients with chronic kidney disease. Clin Lab 59:1121–8
   PubMed Web of Science ®Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, et al. (1985). Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–9
   PubMed Web of Science ®Google Scholar
• McIntyre CW, Harrison LE, Eldehni MT, et al. (2011). Circulating endotoxemia: a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease. Clin J Am Soc Nephrol 6:133–41
   PubMed Web of Science ®Google Scholar
• Menzaghi C, Bacci S, Salvemini L, et al. (2013). Serum resistin, cardiovascular disease and all-cause mortality in patients with type 2 diabetes. PLoS One 8:e64729
   PubMed Web of Science ®Google Scholar
• Meuwese CL, Snaedal S, Halbesma N, et al. (2011). Trimestral variations of C-reactive protein, interleukin-6 and tumour necrosis factor-α are similarly associated with survival in haemodialysis patients. Nephrol Dial Transplant 26:1313–8
   PubMed Web of Science ®Google Scholar
• Migita K, Maeda Y, Miyashita T, et al. (2006). The serum levels of resistin in rheumatoid arthritis patients. Clin Exp Rheumatol 24:698–701
   PubMed Web of Science ®Google Scholar
• Ohashi N, Kato A, Misaki T, et al. (2008). Association of serum adiponectin levels with all-cause mortality in hemodialysis patients. Intern Med 47:485–91
   PubMed Web of Science ®Google Scholar
• Patel L, Buckels AC, Kinghorn IJ, et al. (2003). Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 300:472–6
   PubMed Web of Science ®Google Scholar
• Rao M, Wong C, Kanetsky P, et al. (2007). Cytokine gene polymorphism and progression of renal and cardiovascular diseases. Kidney Int 72:549–56
   PubMed Web of Science ®Google Scholar
• Ravani P, Tripepi G, Malberti F, et al. (2005). Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 16:2449–55
   PubMed Web of Science ®Google Scholar
• Singer JR, Palmas W, Teresi J, et al. (2012). Adiponectin and all-cause mortality in elderly people with type 2 diabetes. Diabetes Care 35:1858–63
   PubMed Web of Science ®Google Scholar
• Sook Lee E, Park SS, Kim E, et al. (2013). Association between adiponectin levels and coronary heart disease and mortality: a systematic review and meta-analysis. Int J Epidemiol 42:1029–39
   PubMed Web of Science ®Google Scholar
• Spoto B, Mattace-Raso F, Sijbrands E, et al. (2013). Resistin and all-cause and cardiovascular mortality: effect modification by adiponectin in end-stage kidney disease patients. Nephrol Dial Transplant 28:iv181–7
   PubMedGoogle Scholar
• Steppan CM, Bailey ST, Bhat S, et al. (2001). The hormone resistin links obesity to diabetes. Nature 409:307–12
   PubMed Web of Science ®Google Scholar
• Sunden-Cullberg J, Nyström T, Lee ML, et al. (2007). Pronounced elevation of resistin correlates with severity of disease in severe sepsis and septic shock. Crit Care Med 35:1536–42
   PubMed Web of Science ®Google Scholar
• Tsai YC, Lee CT, Huang TL, et al. (2007). Inflammatory marker but not adipokine predicts mortality among long-term hemodialysis patients. Mediators Inflamm 2007:19891
   PubMed Web of Science ®Google Scholar
• Wu XM, Lin YH, Chen A, et al. (2012). Prognostic significance of adipocytokines in systolic heart failure patients. Eur J Clin Invest 42:1079–86
   PubMed Web of Science ®Google Scholar
• Wu ZJ, Cheng YJ, Gu WJ, et al. (2014). Adiponectin is associated with increased mortality in patients with already established cardiovascular disease: a systematic review and meta-analysis. Metabolism 63:1157–66
   PubMed Web of Science ®Google Scholar
• Zhang MH, Na B, Schiller NB, et al. (2011). Association of resistin with heart failure and mortality in patients with stable coronary heart disease: data from the heart and soul study. J Card Fail 17:24–30
   PubMed Web of Science ®Google Scholar
• Zoccali C, Mallamaci F, Tripepi G, et al. (2002). Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13:134–41
   PubMed Web of Science ®Google Scholar